Evidence map›Paper›PMID 25533804›Full record

ArticleLeukemia2015

A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.

F Abate, M Todaro, J-A van der Krogt, M Boi, I Landra, R Machiorlatti, F Tabbò, K Messana, C Abele, A Barreca and 32 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses viaProceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. TRAF1 Signaling in Human Health and Disease.Frontiers in immunology · 2018
    Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

42 authors at 13 institutions in 4 countries.

F Abate1] Department of Control and Computer Engineering, Politecnico di Torino, Turin, Italy [2] Department of Biomedical Informatics, Center for Computational Biology and Bioinformatics, Columbia University, New York, NY, USA [3] Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Turin, Italy.
M TodaroDepartment of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Turin, Italy.
J-A van der KrogtDepartment of Human Genetics, KU Leuven, Leuven, Belgium.
M Boi1] Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Turin, Italy [2] Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland.
I LandraDepartment of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Turin, Italy.
R MachiorlattiDepartment of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Turin, Italy.
F TabbòDepartment of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Turin, Italy.
K MessanaDepartment of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Turin, Italy.
C AbeleDepartment of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Turin, Italy.
A BarrecaDepartment of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Turin, Italy.
D NoveroDepartment of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Turin, Italy.
M GaudianoDepartment of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Turin, Italy.
S AlibertiDepartment of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Turin, Italy.
F Di GiacomoDepartment of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Turin, Italy.
T TousseynTranslational Cell and Tissue Research, KU Leuven, Department of Pathology, UZ Leuven, Leuven, Belgium.
E LasorsaDepartment of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Turin, Italy.
R CrescenzoDepartment of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Turin, Italy.
L BessoneDepartment of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Turin, Italy.
E FicarraDepartment of Control and Computer Engineering, Politecnico di Torino, Turin, Italy.
A AcquavivaDepartment of Control and Computer Engineering, Politecnico di Torino, Turin, Italy.
A RinaldiLymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland.
M PonzoniPathology & Lymphoid Malignancies Units, San Raffaele Scientific Institute, Milan, Italy.
D L LongoMolecular Imaging Center, Department of Chemistry IFM and Molecular Imaging Center, University of Torino, Turin, Italy.
S AimeMolecular Imaging Center, Department of Chemistry IFM and Molecular Imaging Center, University of Torino, Turin, Italy.
M ChengTeva Pharmaceuticals, Inc, North Wales, PA, USA.
B RuggeriTeva Pharmaceuticals, Inc, North Wales, PA, USA.
P P PiccalugaInstitute of Hematology and Medical Oncology L. and A. Seràgnoli, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
S PileriInstitute of Hematology and Medical Oncology L. and A. Seràgnoli, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
E TiacciInstitute of Hematology, University of Perugia, Ospedale S. Maria della Misericordia, S. Andrea delle Fratte, Perugia, Italy.
B FaliniInstitute of Hematology, University of Perugia, Ospedale S. Maria della Misericordia, S. Andrea delle Fratte, Perugia, Italy.
B Pera-GreselyDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA.
L CerchiettiDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA.
J IqbalThe Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
W C ChanDepartment of Pathology, City of Hope Medical Center, Duarte, CA, USA.
L D ShultzThe Jackson Laboratory, Bar Harbor, ME, USA.
I Kwee1] Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland [2] IDSIA Dalle Molle Institute for Artificial Intelligence, Manno, Switzerland [3] SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.
R Piva1] Department of Control and Computer Engineering, Politecnico di Torino, Turin, Italy [2] Department of Pathology, and NYU Cancer Center, New York University School of Medicine, New York, NY, USA.
I WlodarskaDepartment of Human Genetics, KU Leuven, Leuven, Belgium.
R RabadanDepartment of Biomedical Informatics, Center for Computational Biology and Bioinformatics, Columbia University, New York, NY, USA.
F Bertoni1] Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland [2] Lymphoma Unit, IOSI Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
G Inghirami1] Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Turin, Italy [2] Department of Pathology, and NYU Cancer Center, New York University School of Medicine, New York, NY, USA [3] Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.
European T-cell Lymphoma Study Group
University of Turin · ITPolytechnic University of Turin · ITKU Leuven · BEAzienda Ospedaliera di Perugia · ITCornell University · USInstitute of Oncology Research · CHTeva Pharmaceuticals (United States) · USUniversity of Bologna · ITCity Of Hope National Medical Center · USColumbia University · USDalle Molle Institute for Artificial Intelligence Research · CHJackson Laboratory · USUniversity of Nebraska Medical Center · US

Funding

Shared Resource ManagementP30CA034196 · NCI · JACKSON LABORATORY · PI William Carl Skarnes · 1985 to 2026
$61.9M
Nation Center: Multi-Scale Study- Cellular Networks(RMI)U54CA121852 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2005 to 2015
$37.4M
Modeling the temporal succession of phenotypes & environnnental cuesP50MH094267 · NIMH · UNIVERSITY OF CHICAGO · PI RZHETSKY, ANDREY · 2011 to 2015
$10.2M
Role of acetyltransferase gene inactivation in follicular lymphoma pathogenesisR01CA164152 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI DALLA-FAVERA, RICCARDO · 2012 to 2016
$1.6M
NCI NIH HHS 1R01CA164152-01NCI NIH HHS 1 U54 CA121852-05NCI NIH HHS CA034196NCI NIH HHS P30 CA034196NCI NIH HHS R01 CA164152NCI NIH HHS U54 CA121852NIMH NIH HHS 1 P50 MH094267-01NIMH NIH HHS P50 MH094267
6 · The paper itself

Abstract

Although anaplastic large-cell lymphomas (ALCL) carrying anaplastic lymphoma kinase (ALK) have a relatively good prognosis, aggressive forms exist. We have identified a novel translocation, causing the fusion of the TRAF1 and ALK genes, in one patient who presented with a leukemic ALK+ ALCL (ALCL-11). To uncover the mechanisms leading to high-grade ALCL, we developed a human patient-derived tumorgraft (hPDT) line. Molecular characterization of primary and PDT cells demonstrated the activation of ALK and nuclear factor kB (NFkB) pathways. Genomic studies of ALCL-11 showed the TP53 loss and the in vivo subclonal expansion of lymphoma cells, lacking PRDM1/Blimp1 and carrying c-MYC gene amplification. The treatment with proteasome inhibitors of TRAF1-ALK cells led to the downregulation of p50/p52 and lymphoma growth inhibition. Moreover, a NFkB gene set classifier stratified ALCL in distinct subsets with different clinical outcome. Although a selective ALK inhibitor (CEP28122) resulted in a significant clinical response of hPDT mice, nevertheless the disease could not be eradicated. These data indicate that the activation of NFkB signaling contributes to the neoplastic phenotype of TRAF1-ALK ALCL. ALCL hPDTs are invaluable tools to validate the role of druggable molecules, predict therapeutic responses and implement patient specific therapies.

Indexed as

Drug Resistance, NeoplasmAnaplastic Lymphoma KinaseAnimalsBlotting, WesternFlow CytometryGene Expression ProfilingHigh-Throughput Nucleotide SequencingHumansImmunoprecipitationIn Situ Hybridization, FluorescenceLymphoma, Large-Cell, AnaplasticMiceMice, Inbred NODNF-kappa BPositive Regulatory Domain I-Binding Factor 1Proteasome InhibitorsALK protein, humanAlk protein, mouseAnaplastic Lymphoma KinaseMYC protein, humanNF-kappa BPositive Regulatory Domain I-Binding Factor 1PRDM1 protein, humanProteasome InhibitorsProto-Oncogene Proteins c-mycReceptor Protein-Tyrosine KinasesRepressor ProteinsRNA, MessengerTNF Receptor-Associated Factor 1TP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID25533804
PMCPMC4864432
OpenAlexW2021247755

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.